VERTEX PHARMACEUTICALS INC / MA (VRTX)

Every figure this model derived for VRTX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 496,800,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 7,852,400,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 12,543,700,000 AssetsCurrent 2026-06-30
current liabilities 3,937,900,000 LiabilitiesCurrent 2026-06-30
equity 20,247,900,000 StockholdersEquity 2026-06-30
interest expense 12,500,000 InterestPaidNet 2026-06-30
ocf 4,292,900,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 12,587,200,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 689,100,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up VRTX on one particular measure came for.

RatioValue
cash operating margin45.19
current ratio3.19
current ratio reported3.19
deferred revenue growth-13.92
dilution pct0.04
ebit cagr3.0
ebit yoy21.76
ev ebit27.43
ev owner earnings42.18
ev sales10.41
fcf margin30.16
growth cv0.35
interest cover382.17
operating margin37.95
owner earnings margin24.68
revenue growth10.23
revenue growth per share10.19
roic30.17
rule of 4048.18
sbc pct revenue5.47

What to be careful about

What this model itself distrusts about VRTX's figures. Written by the derivation as it ran, not added afterwards.